Anavex Life Sciences Corp (AVXL)

[Jonjones325]

I fully understand the in-licensing strategy. However, I don't know if it will work for multiple indications and 1 compound. Let's say Biogen in-licensed 2-73 for MS. Then 2-73 gets approved for Rett's. All of a sudden, doctors can start prescribing 2-73 off label for other indications. What good then is the in-licensing for MS?

I guess, they could eventually get it approved for MS and then receive the profits for that indication. But what happens if and when it is approved for multiple indications. Who is getting treated for what and who gets paid?

It seems complicated. I would bet any BP would come to a similar conclusion. Instead just control the entire compound.

Am I over-complicating this?